Volume 17, Number 11—November 2011
CME ACTIVITY - Research
Global Distribution and Epidemiologic Associations of Escherichia coli Clonal Group A, 1998–2007
Table 1
Continent, location† |
Year(s) of isolation |
Total no. isolates |
S, % |
Source, no. isolates |
No. CGA isolates/total no. (%) | ||||||
Specimen type |
|
Setting |
Child‡ | ||||||||
Urine |
Nonurine |
|
In |
Out |
R |
S | |||||
Africa |
|
|
|
|
|
|
|
|
|
|
|
Ile-Ife, Nigeria |
2004 |
41 |
NK |
41 |
0 |
|
22 |
19 |
4 |
3/36 (8) |
0/5 (0) |
Lusaka, Zambia |
2001 |
51 |
59 |
4 |
37 |
|
NK |
NK |
0 |
0/31 (0) |
0/20 (0) |
Asia |
|
|
|
|
|
|
|
|
|
|
|
Chandigarh, India |
2006 |
50 |
60 |
37 |
13 |
|
34 |
16 |
9 |
0/36 (0) |
0/14 (0) |
Kitakyushu, Japan |
2001–2005 |
56 |
80 |
37 |
19 |
|
36 |
20 |
7 |
1/29 (3) |
0/27 (0) |
Singapore |
2002 |
50 |
60 |
43 |
7 |
|
NK |
NK |
0 |
1/25 (4) |
0/25 (0) |
Taiwan |
1998–2004 |
320 |
46 |
256 |
64 |
|
66 |
254 |
73 |
8/161 (5) |
8/159 (5) |
Australia/New Zealand |
|
|
|
|
|
|
|
|
|
|
|
Canberra, Australia |
1998–2001 |
121 |
80 |
50 |
71 |
|
0 |
121 |
5 |
10/60 (17) |
3/61 (5) |
Palmerston North, New Zealand |
2006 |
51 |
78 |
36 |
15 |
|
18 |
33 |
3 |
1/24 (4) |
0/27 (0) |
Europe |
|
|
|
|
|
|
|
|
|
|
|
Zagreb, Croatia |
2001–2002 |
91 |
81 |
44 |
47 |
|
58 |
33 |
0 |
8/46 (17) |
1/45 (2) |
Athens, Greece |
2003–2005 |
149 |
66 |
96 |
53 |
|
92 |
57 |
3 |
15/75 (20) |
1/74 (1) |
Varese, Italy |
2006 |
51 |
75 |
35 |
16 |
|
31 |
20 |
3 |
0/26 (0) |
0/25 (0) |
Santander, Spain |
2003 |
53 |
70 |
35 |
18 |
|
19 |
34 |
9 |
0/26 (0) |
2/27 (7) |
Bellinzona, Switzerland |
2006 |
54 |
75 |
36 |
18 |
|
34 |
20 |
2 |
3/27 (11) |
0/27 (0) |
North America |
|
|
|
|
|
|
|
|
|
|
|
Calgary, Alberta, Canada |
2001 |
54 |
78 |
36 |
18 |
|
34 |
20 |
10 |
6/27 (22) |
1/27 (4) |
United States |
|
|
|
|
|
|
|
|
|
|
|
Denver, CO |
2001 |
100 |
78 |
50 |
50 |
|
50 |
50 |
0 |
17/50 (34) |
3/50 (6) |
West Haven, CT |
2006 |
34 |
76 |
24 |
10 |
|
17 |
17 |
0 |
0/16 (0) |
0/18 (0) |
Chicago, Il |
2001 |
60 |
74 |
40 |
20 |
|
37 |
23 |
0 |
0/30 (0) |
0/30 (0) |
Lexington, KY |
2001 |
60 |
80 |
40 |
20 |
|
7 |
53 |
5 |
3/30 (10) |
1/30 (3) |
Petoskey, MI |
2001 |
45 |
89 |
NK. |
NK |
|
NK |
NK |
0 |
5/21 (24) |
0/24 (0) |
Duluth, MN |
2001 |
50 |
90 |
39 |
11 |
|
8 |
42 |
0 |
4/26 (15) |
0/24 (0) |
Minneapolis, MN† |
2001 |
66 |
87 |
56 |
10 |
|
15 |
51 |
0 |
1/26 (4) |
1/40 (3) |
Minneapolis, MN† |
2001 |
46 |
90 |
38 |
8 |
|
21 |
25 |
0 |
0/18 (0) |
0/28 (0) |
Northfield, MN |
2001 |
24 |
95 |
24 |
0 |
|
0 |
24 |
0 |
1/12 (8) |
0/12 (0) |
St. Louis Park, MN |
2001 |
64 |
83 |
64 |
0 |
|
0 |
64 |
7 |
9/32 (28) |
3/32 (9) |
Fargo, ND |
2001 |
54 |
90 |
49 |
5 |
|
5 |
49 |
11 |
1/27 (4) |
1/27 (4) |
Philadelphia, PA |
2006 |
94 |
78 |
87 |
7 |
|
13 |
81 |
0 |
2/22 (9) |
0/72 (0) |
Houston, TX |
2001 |
60 |
65 |
40 |
20 |
|
35 |
25 |
9 |
1/30 (3) |
1/30 (3) |
Salt Lake City, UT |
2001 |
47 |
85 |
31 |
16 |
|
24 |
23 |
4 |
1/21 (5) |
1/26 (4) |
South/Central America |
|
|
|
|
|
|
|
|
|
|
|
Concepción, Chile |
2006 |
51 |
57 |
36 |
15 |
|
33 |
18 |
NK |
5/24 (21) |
1/27 (4) |
Cali, Columbia |
2005–2006 |
51 |
52 |
36 |
15 |
|
27 |
24 |
16 |
3/24 (13) |
1/27 (4) |
Panama City, Panama |
2007 |
54 |
36 |
36 |
18 |
|
19 |
35 |
52 |
1/27 (4) |
1/27 (4) |
Lima, Peru |
2002–2006 |
58 |
82 |
39 |
19 |
|
30 |
28 |
18 |
4/58 (7) |
Not done
*S, susceptible to trimethoprim/sulfamethoxazole; in, inpatient; out, outpatient; CGA, clonal group A; R, resistant to trimethoprim/sulfamethoxazole; NK, not known.
*S, susceptible to trimethoprim/sulfamethoxazole; in, inpatient; out, outpatient; CGA, clonal group A; R, resistant to trimethoprim/sulfamethoxazole; NK, not known. |
*S, susceptible to trimethoprim/sulfamethoxazole; in, inpatient; out, outpatient; CGA, clonal group A; R, resistant to trimethoprim/sulfamethoxazole; NK, not known.
†A list of the 32 centers is provided in the Technical Appendix. Note that 2 centers were located in Minneapolis.
‡<18 y of age.
1Investigators who contributed data are listed at the end of this article.